N/A N=81 Effects of Different Surgical Methods to Treat Obesity
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=23 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
Hypogonadism · Severe Obesity
Primary: Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion — 12.6; 8.9; 12.8; 3.7 Percent change in muscle strength
N/A N=45 Aerobic Training and Non-Exercise Physical Activity
Central Obesity · Obesity
Primary: Change in Waist Circumference — -1.3; -1.9; -4.1 cm — p=0.074
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
Phase 2 N=22 Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
Aging · Obesity · Insulin Resistance
Primary: Change in Total Mass and Regional Adipose Adiposiy — 0.3; -1.4; -0.9; -0.7 kilograms — p=0.77
Phase 3 N=83 Lifestyle Intervention and Testosterone Replacement in Obese Seniors
Obesity and Hypogonadism
Primary: Change in the Physical Performance Test — 4.6; 4.9 units on a scale — p=0.58
N/A N=142 Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
Obesity
Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L
Phase 3 N=59 Rosuvastatin in Visceral Adiposity
Abdominal Obesity
Primary: Change in Visceral Adipose Tissue Area Measured by Computed Tomography. — -1.5; 2.8 cm2
Phase 2 N=125 PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
Healthy · Obese
Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day
Phase 4 N=137 Testosterone Replacement in Men With Diabetes and Obesity
Hypogonadism
Primary: Insulin Sensitivity — 6.66; 5.12; 11.37; 12.93 mg/kg fat free mass/min
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
N/A N=28 Investigating the Physiological Effects of Weight Loss on Male Fertility
Male Infertility · Obesity · Weight Loss
Primary: Sperm Concentration — 53.6; 58.5; 20.1; 15 million sperms/mL
N/A N=12 The Effects of Alcohol Consumption on Central Adiposity
Alcohol Drinking · Weight Loss · Adiposity
Primary: Change in Central (Abdominal) Adiposity — -0.250; -0.071 kg — p=<0.231
N/A N=33 Metabolic Effects of Androgenicity in Aging Men and Women
Aging · Insulin Resistance
Primary: Insulin Sensitivity — -0.16; 2.62; -0.50; 1.83 micro International Units/mL — p=0.023
N/A N=9 Toward an Automated Method of Abdominal Fat Segmentation of MR Images
Obesity
Primary: Visceral Fat Volume With Automated Analysis — 994 cubic centimeters
N/A N=80 Engaging Rural Men With Mobile Technologies for Weight Loss
Weight Loss
Primary: Mean Change in Weight by Randomized Group — -7.03; -4.14 kilograms
N/A N=12 Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women
Central Obesity
Primary: Body Fat (kg) — 40.96; 40.12; 2.94; 4.26 kg
N/A N=28 Relative Sarcopenia and Cardiometabolic Risk in Young Adults With Obesity
Overweight and Obesity · Insulin Resistance
Primary: Percent Change in Serum Myostatin Levels From Pre- to 3 Hours Post-exercise — -6.9; 8.5 % change in serum myostatin — p=0.303
N/A N=60 Effects of Electrical Muscle Stimulation on Waist Circumference in Adults
Abdominal Obesity
Primary: Waist Circumference — 87.0; 89.4 cm
Phase 2 N=60 Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Abdominal Obesity · Growth Hormone Deficiency
Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2
Phase 3 N=302 Enhancing Fitness in Older Pre-diabetic Veterans
Impaired Glucose Tolerance · Obesity · Diabetes
Primary: Fasting Insulin — 10.26; 10.39 uIU/ml
N/A N=271 Weight Discrimination and Poor Cardiovascular Health
Obesity
Primary: Negative Affect — 1.43; 1.29 score on a scale — p=.007
N/A N=103 Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up
Diabetes Mellitus · Hypertension · Ischemic Heart Disease
Primary: Exploring Insulin Sensitivity After 10-20 Years of Follow-up — 7 mg/kg/min — p=<0.05
N/A N=40 Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy
Obesity · Prostate Cancer
Primary: Impact of Weight Loss Before and Weight Maintenance After Prostate Cancer (PCa) Surgery on Immunosuppressive Factors — 19.29; 17.37; 17.68; 12.76 count of cells — p=0.6489
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14
N/A N=20 Multimodel Exercise and Weight Loss in Older Obese Veterans With Dysmobility
Obesity · Dysmobility
Primary: Change in 6 Minute Walk Distance — 1137; 1195 feet — p=0.03
N/A N=29 PowerUp for Health: A Diabetes Prevention Program for Men
Type 2 Diabetes · Men
Primary: Change in Weight in Pounds — 3.8 percentage of body weight lost
N/A N=43 Vitamin D Supplementation to Obese Chinese Males
Obesity · Insulin Resistance
Primary: Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L) — 116.7; 181.3; 46.1; 52.8 nmol/L
N/A N=29 Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study
Overweight and Obesity · PreDiabetes · Type 2 Diabetes
Primary: Change in BMI — 0.43; 0; 4.4; 0 kg/m2 — p=0.2
Phase 4 N=88 Optimizing Body Composition for Function in Older Adults
Obesity · Overweight With Indications for Weight Loss
Primary: Appendicular Non-bone Lean Mass — -2.53; -2.49; -2.04; -1.45 kg